Switch theme
Sign up to access all valuation multiples
Green Cross Holdings Corp manufactures and sells medicines and medical supplies. The company's products include Plasma Derivatives, Vaccines, Prescription Drugs and Over-the-counter Drugs. Some of the drugs offered by the company comprise of Acustop Cataplasma, Zenol Cool Type, Green-VIII inj and Hunterase.
1967
n/a
Last FY Revenue $1.6B
Last FY EBITDA $155M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, GC Biopharma achieved revenue of $1.6B and an EBITDA of $155M.
GC Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GC Biopharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | XXX | $453M | XXX | XXX | XXX |
| Gross Margin | XXX | 28% | XXX | XXX | XXX |
| EBITDA | XXX | $155M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 10% | XXX | XXX | XXX |
| EBIT | XXX | -$7.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | 0% | XXX | XXX | XXX |
| Net Profit | XXX | $17.5M | XXX | XXX | XXX |
| Net Margin | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | $739M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, GC Biopharma's stock price is KRW 16287 (or $12).
GC Biopharma has current market cap of KRW 739B (or $540M), and EV of KRW 2.07T (or $1.5B).
See GC Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $540M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, GC Biopharma has market cap of $540M and EV of $1.5B.
GC Biopharma's trades at 0.9x EV/Revenue multiple, and 9.7x EV/EBITDA.
Equity research analysts estimate GC Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GC Biopharma's P/E ratio is not available.
See valuation multiples for GC Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $540M | XXX | $540M | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -193.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 30.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGC Biopharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
GC Biopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GC Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GC Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GC Biopharma acquired XXX companies to date.
Last acquisition by GC Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . GC Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GC Biopharma founded? | GC Biopharma was founded in 1967. |
| Where is GC Biopharma headquartered? | GC Biopharma is headquartered in South Korea. |
| Who is the CEO of GC Biopharma? | GC Biopharma's CEO is Mr. Il-Seop Heo. |
| Is GC Biopharma publicy listed? | Yes, GC Biopharma is a public company listed on KRX. |
| What is the stock symbol of GC Biopharma? | GC Biopharma trades under 005250 ticker. |
| When did GC Biopharma go public? | GC Biopharma went public in 1978. |
| Who are competitors of GC Biopharma? | Similar companies to GC Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of GC Biopharma? | GC Biopharma's current market cap is $540M |
| Is GC Biopharma profitable? | Yes, GC Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
